Nancy Agee Buys 3,411 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) Director Nancy Agee purchased 3,411 shares of Precigen stock in a transaction dated Friday, August 21st. The shares were bought at an average cost of $7.23 per share, for a total transaction of $24,661.53. Following the transaction, the director directly owned 309,187 shares of the company’s stock, valued at approximately $2,235,422.01. The trade was a 1.12% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Precigen Stock Performance

Shares of PGEN opened at $7.42 on Thursday. The stock has a market capitalization of $2.65 billion, a PE ratio of -7.13 and a beta of 1.02. The business’s fifty day moving average price is $5.96 and its 200 day moving average price is $4.71. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen, Inc. has a 12-month low of $2.99 and a 12-month high of $7.72.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The business had revenue of $54.98 million for the quarter, compared to analysts’ expectations of $27.98 million. The firm’s revenue was up 6322.7% compared to the same quarter last year. Equities research analysts forecast that Precigen, Inc. will post 0.25 EPS for the current year.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong PAPZIMEOS sales and profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the prior quarter. The product’s performance helped the company achieve quarterly profitability and represents a significant commercial inflection point. Precigen second-quarter update
• Positive Sentiment: Pipeline progress supports the growth outlook: PRGN-2009 is advancing in HPV-driven cancers, and management highlighted broader potential for the AdenoVerse platform. The combination of growing product revenue and additional pipeline opportunities is strengthening the investment case. AdenoVerse platform and PRGN-2009 update
• Positive Sentiment: Favorable external sentiment: Zacks included PGEN among five biotech stocks worth considering, citing industry momentum, pipeline progress and the company’s portfolio. Recent coverage also notes a consensus “Moderate Buy” rating and a $14.50 price target, although analyst opinions remain mixed. Zacks biotech stock selection
• Positive Sentiment: Director buying: Director Nancy Agee purchased 3,411 shares at $7.23, increasing her ownership by 1.12%. The insider purchase may signal confidence in Precigen’s outlook.
• Neutral Sentiment: COO sales were administrative: COO Rutul Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The transactions reduce his holdings but are less bearish than discretionary selling.
• Neutral Sentiment: Momentum and risk: PGEN reached a new one-year high, reinforcing bullish momentum, but elevated valuation expectations and the company’s historically negative net margin leave the stock sensitive to future sales and clinical updates. Precigen reaches a new one-year high

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright raised their price target on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Zacks Research raised Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Precigen presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PGEN. State of Wyoming acquired a new stake in Precigen during the first quarter valued at $27,000. NBC Securities Inc. acquired a new stake in shares of Precigen during the 4th quarter valued at about $38,000. Caitong International Asset Management Co. Ltd acquired a new position in Precigen in the third quarter worth approximately $39,000. Royal Bank of Canada raised its position in Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Precigen during the third quarter valued at approximately $41,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.